Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fusion Antibodies Plc ( (GB:FAB) ) has shared an announcement.
Fusion Antibodies plc has released a video featuring Dr. Richard Buick, CSO, discussing the science and technology behind their OptiMAL® library, which is set to launch commercially in December 2025. The OptiMAL® library, protected by a US patent, is designed to discover novel human antibodies and is part of the company’s strategy to provide innovative platforms that accelerate drug development, potentially enhancing their market position and offering significant benefits to stakeholders in the pharmaceutical and diagnostic industries.
The most recent analyst rating on (GB:FAB) stock is a Sell with a £11.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Underperform.
Fusion Antibodies Plc’s overall stock score is primarily driven by its challenging financial performance and weak technical indicators. The company’s negative profitability and cash flow issues are significant concerns, while the bearish technical signals suggest further downside risk. The valuation metrics also reflect the company’s financial difficulties, contributing to the low overall score.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organisation specializing in antibody engineering services for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company offers a broad range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a strong international client base, including eight of the top ten global pharmaceutical companies by revenue, and aims to expedite drug development processes through advanced technological platforms.
Average Trading Volume: 1,178,569
Technical Sentiment Signal: Buy
Current Market Cap: £13.92M
For an in-depth examination of FAB stock, go to TipRanks’ Overview page.